Memo Therapeutics closes Series B Financing at CHF 37m . The advisors
Memo Therapeutics, specialists in the field of antibody discovery and development, has closed an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from a combination of strategic and financial investors, including Adjuvant Capital, Fresenius Medical Care Ventures, GF Group, Verve Ventures, Vesalius Biocapital and Zürcher Kantonalbank.
The proceeds will be used to advance clinical development of its best- and first-in-class neutralizing antibody, MTX-005, targeting BK virus infection in renal transplant patients through Phase 2 clinical development. In addition, the funding will be used to develop and expand its antibody pipeline and secure new partnering agreements.
Memo Therapeutics recently received a CHF10.5 million commitment from the Swiss Federal Funding Programme for COVID-19 Medicines to advance COVAB 36, a potent, fully human monoclonal antibody administered via inhalation for the treatment of SARS-CoV-2 infections, into clinical development.
The advisors
BGPartner assisted Memo Therapeutics in the negotiations and advised on all Swiss legal matters regarding this transaction. The team was led by Oliver Gnehm (partner, pictured above) and consisted of Victoria Marty (associate) and Thomas Gysin (senior associate).
Walder Wyss advised Adjuvant Capital, a life sciences investment fund that backs ambitious companies developing drugs, vaccines, diagnostics, medical devices, and other technologies. The Walder Wyss team was led by partner Alexander Gutmans (corporate/m&a and venture capital, pictured left) and included senior associate Michelle Bruni (corporate/m&a and tax), associate Karina Tschon (corporate/m&a and venture capital) and associate Bojan Momic (corporate/employment).